Corporate PresentationDownload January 2026 Presentation Select HighlightsJanuary 12, 2026News: Financing from Institutional Investors & LillyRead More »January 12, 2026News: REX-8756 Phase 1 MilestoneRead More »May 8, 2025SID Conference: BTK DataAccess Poster » Latest Press ReleasesJanuary 12, 2026Recludix Pharma Announces Equity Financing to Advance Clinical Development of Novel SH2 Domain InhibitorsRead More »January 12, 2026Recludix Pharma Announces Dosing of First Subjects in a Phase 1 Study of REX-8756, a Potent and Selective Oral STAT6 Inhibitor, and Achieves Associated $20 Million Milestone Payment Under Collaboration with SanofiRead More »January 8, 2026Recludix Pharma Bolsters Scientific Advisory Board with Acclaimed Leaders in the Fields of Rheumatology, Dermatology and JAK/STAT BiologyRead More »January 7, 2026Recludix Pharma to Present at the Annual J.P. Morgan Healthcare ConferenceRead More » More Press Releases Events and PresentationsJanuary 15, 2026 at 9:30 a.m. PTJ.P. Morgan Healthcare ConferenceConference Website »November 11, 2025 at 11:20 a.m. ETStifel 2025 Healthcare ConferenceRegister Here »November 10, 2025 at 1:30 p.m. ET Guggenheim Second Annual Healthcare Innovation ConferenceRegister Here »September 16, 2025 3:00 p.m. ETStifel 2025 Virtual Immunology and Inflammation ForumAccess Webcast » More Events and Presentations News Coverage HighlightsAugust 7, 2023BioCentury: Recludix: targeting STATs via their SH2 domainsRead More »July 20, 2023BioWorld: Recludix enters a potential $1.2B deal with SanofiRead More »July 20, 2023SCRIP: Sanofi Adds To Immunology Pipeline In Collaboration With Recludix Read More »July 20, 2023Fierce Biotech: Sanofi pays $125M to go after undruggable inflammatory target with Recludix’s preclinical programRead More »July 20, 2023Endpoints News: Following Dupixent’s rise, Sanofi heads downstream in immunology for $125M small molecule pact with RecludixRead More »
